In-Press Preview B-cells are key contributors to chronic autoimmune pathology in multiple sclerosis (MS). Clonally related B-cells exist in the cerebrospinal fluid (CSF), meninges, and central nervous system (CNS) parenchyma of MS patients. We sought to investigate the presence of clonally related B-cells over time by performing immunoglobulin heavy chain variable region repertoire sequencing on B-cells from longitudinally collected blood and CSF samples of MS patients (n=10). All patients were untreated at the time of the initial sampling; the majority (n=7) were treated with immune modulating therapies 1.2 (+/-0.3 SD) years later during the second sampling. We found clonal persistence of B-cells in the CSF of five patients; these B-cells were frequently immunoglobulin (Ig) class-switched and CD27+. We identified specific blood B-cell subsets that appear to provide input into CNS repertoires over time. We demonstrate complex patterns of clonal B-cell persistence in CSF and blood, even in patients on immune modulating therapy. Our findings support the concept that peripheral B-cell activation and CNS-compartmentalized immune mechanisms can in part therapy-resistant.
Introduction
B lymphocytes (B-cells) are key players in the immunopathology of multiple sclerosis (MS) (1) (2) (3) (4) (5) (6) . B-cell depleting anti-CD20 antibody therapies effectively reduce relapsing MS disease activity and slow the accumulation of disability in relapsing and primary progressive disease (2, 3, 7) . Early on in the disease course, B-cells enter the CNS, CSF, and meningeal compartments (8) (9) (10) where they become compartmentalized and likely contribute to ongoing CNS tissue damage and consequential disability progression.
Immunoglobulin gene transcripts, particularly heavy chain variable regions (Ig-VH), provide molecular fingerprints that permit temporal and spatial tracking of clonally related B-cells (11) (12) (13) . Single time-point immune repertoire studies in MS patients showed that there is an anatomic continuum of clonally related Bcells extending from MS lesions in the brain parenchyma, to cerebrospinal fluid (CSF), meningeal inflammatory infiltrates, cervical lymph nodes, and peripheral blood (PB) (11, 12, (14) (15) (16) . Individual MS patients have a characteristic CSF immunoglobulin electrophoretic pattern (oligoclonal bands [OCBs] ) that persists over many years; the stability in the pattern of OCBs within a patient is considered evidence that clonally related B-cells are long-lived in the central nervous system (CNS) (17, 18) . However, because multiple B-cell clones can give rise to a single OCB (16) , higher resolution genomic techniques are required to confirm this hypothesis.
Here, we were interested to determine persistence of clonally related B-cells in the CSF and in PB over time. Using previously described immune repertoire sequencing technology and bioinformatics tools (8),
we analyzed Ig-VH sequences (IgG-VH and IgM-VH) (19) from 10 patients' PB and CSF B-cell subsets at two time points to track related B-cells over time and across compartments. Work by others previously described two untreated MS patients with clonally related CSF B-cells over time (20) . Here, we were interested to understand which specific B-cell subsets comprise clonally related CSF B-cells that remain longitudinally detectable, their clonal relationship to PB B-cells, and whether CSF B-cells persist after treatment with MS immune modulating therapy (IMT). We identified persistent clonally related B-cells in the CSF of five patients, four of whom had initiated IMT between the first and second time points. We also identified patterns of clonal B-cell input from the periphery to the CSF over time, suggesting that functionally diverse CD27+ PB memory B-cells are a likely peripheral reservoir of B-cells involved in MS disease activity.
Results

Patient demographics
10 patients ranging in age from 24 to 52 years old were enrolled (see Table 1 for clinical data and Table S1 for standard laboratory CSF findings). On average, 12.2 mL (+/-3.5 SD) of CSF was collected per patient per time point. Eight patients had relapsing-remitting MS (RRMS), and two had primary progressive MS (PPMS). All were untreated at time point 1 (T1), and seven of the eight RRMS patients were on IMT by time point 2 (T2) ( Table 1 ). Since there were no approved IMTs for PPMS prior to 2017, neither PPMS patient was on an IMT. IMTs used in this cohort varied from lower efficacy to higher efficacy treatments.
Eight of 10 patients (6 treated, 2 untreated) had enhancing and/or new lesions on brain and/or spinal cord MRI at T2 (Table 1 ). All patients had OCBs unique to the CSF at both time points (Table S2 ). In 7/10 patients, we were able to directly compare the OCB pattern at each time point ( Figure S1 ); 5/7 patients had stable band patterns, one had a decrease in band number and one had an increase in band number ( Figure   S1 , Table S2 ).
Flow Cytometry
B-cell subsets were identified and sorted by flow cytometry (MoFlo Astrios). Flow cytometric B-cell subset distribution (see Methods) was determined at T1 and T2 for n=8 patients' CSF and for n=9 patients' PB; flow cytometry was not available for time point 1 CSF (T1-CSF) and peripheral blood (T1-PB) of one patient and for both CSF time points of another patient. When compared to PB, the CSF was enriched in CD19+CD27+IgD-Ig class-switched memory (SM) B-cells ( Figure S2 ), consistent with previous reports (8, 21, 22) .
Immune Repertoire Sequencing
IgG-VH and/or IgM-VH repertoire sequencing (IgSeq) cDNA libraries were prepared from 167 samples.
Samples consisted of PB or CSF sorted B-cell subsets or alternatively bulk CSF or PB mononuclear cells (Table S3) . Sequencing libraries could not be obtained from 16 samples (Table S3) . From the remaining 151 samples, we generated 583,932 (+/-652,920 SD) raw reads per library. 218,401 (+/-308,602 SD) Ig-VH sequences per library were identified from the immunoglobulin heavy chain variable germline segment (IGHV), immunoglobulin heavy chain joining germline segment (IGHJ) and Ig heavy chain complementarity-determining region 3 (H-CDR3) for further analysis (Table S3) . Ig-VH sequences were clustered using a distance metric approach (see Methods). Samples with more B-cells had more Ig-VH clusters ( Figure S3 ) (r = 0.88, p<0.0001 for all samples; r = 0.74, p<0.0001 for PB; r = 0.59, p<0.0001 for CSF, Spearman correlation). Five paucicellular B-cell subsets yielded more Ig-VH clusters than the number of input cells (Table S3) . For these samples, we analyzed the same number of Ig-VH clusters as input cells, choosing the Ig-VH clusters with the greatest number of aligned sequencing reads. Mutational analyses within Ig-VH clusters were not performed as these were not needed for the conclusions of this study.
At T1, we identified CSF Ig-VH clusters that were exclusively IgG-VH in all 10 patients (26.4 (+/-28.3 SD) Ig-VH clusters/patient); of the 10 patients, nine patients also had CSF Ig-VH clusters that contained exclusively IgM-VH (44.8 (+/-57.3 SD) Ig-VH clusters/patient) and in five patients, we found mixed IgM and IgG clusters (5.2 (+/-9.4 SD)) Ig-VH clusters/patient ( Figure S4 ). At T2, we found that all 10 patients' CSF contained Ig-VH clusters that were exclusively IgG-VH (42.6 (+/-72.6 SD) Ig-VH clusters/patient) or exclusively IgM-VH (31.7 (+/-33.9 SD) Ig-VH clusters/patient); in seven patients, there were 6.7 (+/-11.8 SD) Ig-VH clusters/patient that were mixed IgM and IgG ( Figure S4 ). At T1, SM and naïve B-cells were common members of CSF Ig-VH repertoire clusters: these subsets were prevalent in repertories of 3/5 and 2/5 patients with sorted CSF B-cells at T1 (T1-CSF B-cells), respectively (59.6 +/-80.4 SD, 60.8 +/-65.9 SD Ig-VH clusters/patient, respectively; Figure S5 ). SM B-cells commonly contributed to T2-CSF: 5/8 patients with sorted T2-CSF B-cells had SM-predominant repertoires (45.4 +/-65.9 SD Ig-VH clusters/patient) ( Figure S5 ).
Clonally related B-cells persist in MS CSF
In 5 of 10 patients, we identified 'persistent CSF Ig-VH clusters' in which CSF Ig-VH sequences from both time points were represented (Figs. 1-3 ); we thus demonstrate that B-cells found in MS CSF at different time points are clonally related. Aside from Ig-VH sequences that exclusively persisted in CSF ( Figure S6) , we identified three possible associations of CSF Ig-VH clusters with PB repertoires: a T1-PB connection, T2-PB connection, or connections with both PB time point samples (Figure 2) . We found IgG-expressing B-cells, including SM and PC, in persistent CSF Ig-VH clusters of all 5 patients with persistent CSF Ig-VH clusters ( Figure 3 ). In contrast, IgM-expressing B-cell subsets were only found to take part in persistent CSF Ig-VH clusters in two patients (patients 1 and 3) (Figure 3 ). In particular, we did not find naïve CSF Bcells in persistent CSF Ig-VH clusters. (Table S1 , Table S2 ). More of the patients without persistent CSF Ig-VH clusters were men. There was a
numerical (yet not statistically significant) imbalance in the number of patients with relapses in that more of the patients with identified persistent CSF Ig-VH clusters experienced a relapse. There was no significant difference between B-cell subset distribution in patients with or without persistent CSF Ig-VH clusters ( Figure S7 ). We found no correlation between the average reads per cell and our ability to detect persistent CSF Ig-VH clusters (r=0.2, Spearman correlation; p=0.17). The percentage of Ig-VH clusters in CSF that were persistent was similar to the percentage of Ig-VH clusters that were persistent in PB (i.e. Ig-VH clusters formed from PB at both time points) (Table S4 ). This suggests that immune processes such as antigen stimulation and B-cell regulation, which maintain a proportion of B-cell clonal populations in the periphery, may also occur in the CNS.
PB SM and Unswitched Memory (USM) B-cells -potential contributors to CSF B-cell repertoires
Clonal connections between PB and CSF were identified in all patients, irrespective of whether persistent CSF Ig-VH clusters, or clonal relatedness within the same PB and CSF subset, was present ( Figs. 3 and S8 ).
Therefore, to understand which PB B-cell subsets might contribute clonal input to CSF repertoires over time we examined Ig-VH clusters containing T1-PB and T2-CSF members, yet no T1-CSF members. In all 9 patients with sorted T1-PB subsets, T1-PB USM (6 patients) and SM (5 patients) B-cells were related to T2-CSF ( Figure 3 , Figure S8 ). All of these patients except for one (Pt 5) were treated with IMT by T2.
Other T1-PB B-cell subsets sharing repertoires with T2 CSF included naïve (4 patients), DN (3 patients),
and PC (3 patients) ( Figure 3 , Figure S8 ). While overall somatic hypermutation (SHM) rates followed 
Discussion
We identified clonally related B-cells in CSF that were detectable at time-points between 9 and 22 months apart. Given the histopathological and biochemical evidence for B-cell recruitment, survival, and proliferation in the CNS compartment (25) (26) (27) , the ability to detect clonally related CSF B-cells by immune repertoire sequencing over time is likely the result of local persistence (i.e. long-term survival) of B-cells in the functionally connected CNS, CSF, and meningeal compartments. This is perhaps consistent with the disease activity observed in some patients examined in this study, and is also consistent with prior findings of antigen-experienced B cells and soluble immunoglobulin in the CSF that suggests persistence over time.
These cells could constitute a tissue-resident immune repertoire capable of being re-stimulated -either directly or by bystander activation -to re-kindle inflammation; mechanisms that may be shared with rheumatoid arthritis and other tissue-specific chronic autoimmune diseases (28) . cytokine secretion, antigen presentation, and antibody production). Interestingly, even after long-term high efficacy IMT (30, 31) , including intrathecal rituximab (32) , patients continue to be at risk of progression.
Indeed, our findings lend further support to the hypothesis that currently available IMTs may not sufficiently target progression-promoting mechanisms located in the CNS compartment. B cell depleting therapies do not affect CD20-negative plasma cells and oligoclonal antibodies persist in CSF of rituximab treated patients (33, 34) ; future studies are needed to determine whether anti-CD20 therapies deplete persistent clonal B-cells from the CSF, CNS, and meninges and whether doing so reduces disease progression. Our findings may suggest that development of novel therapies that target CNS compartmentalized immune mechanisms could help close an important therapeutic gap.
Disease-driving lymphocytes, including B-cells, are believed to migrate to the CSF and CNS from peripheral stores during phases of MS disease activity (8, 11, 12) . Due to their immunological properties and functionality, SM B-cells are generally believed to be highly relevant to the immune pathology of MS (35) . Indeed, when persistent PB SM cells were clonally related to second time-point CSF B-cells, these T2-CSF cells were nearly always SM and PC. This suggests that, in addition to CSF persistence, a population of potentially disease-relevant PB SM B-cells may have a particular tendency to migrate to the CSF and mature to PC. Also suggestive of peripheral maturation to SM followed by migration and survival in the CNS, rather than local SM to PC maturation in CSF/CNS, we did not find any T2-CSF B-cells that were clonally related to T1-CSF naïve B-cells. In agreement with our previous work, we did not observe any relationships between PB-persistent PCs and CSF PC, further supporting that migration to the CNS occurs at the SM, or earlier B-cell development stage followed by intrathecal maturation to PC rather than immigration of long-lived peripheral PCs.
The efficacy of anti-CD20 B-cell depleting therapy in autoimmune disease is linked to depletion of memory B-cell subsets rather than naïve and transitional subsets (36, 37) . We previously proposed that USM B-cells may play a role in MS due to their appearance in MS CSF during periods of active CNS inflammation (8) .
Interestingly, USM B-cells follow the same depletion and reconstitution pattern as SM B-cells under rituximab therapy (38) . Here, we observed that clonally related SM and USM B-cells, which remain detectable in PB over time, may also have clonal relatives in CSF at the later time point. This finding is consistent with the concept that, upon peripheral activation, CXCR5+ USM and/or SM B-cells home to the brain parenchyma or leptomeninges along a CXCL13 gradient, where they participate in the formation of ectopic, tertiary germinal centers (8, 9, 39, 40) capable of supporting B-cell receptor affinity-maturation and class-switch recombination (41) . Whether USM B-cell receptors undergo Ig class-switching and contribute to high-affinity surface receptor or secreted antibody-mediated immune responses has been debated (42, 43 There are a number of limitations to this study. First, it is important to keep in mind that it is not technically possible to interrogate the entire immune repertoire in a living patient. As a result, persistent B-cells could have gone undetected, and patients in whom we did not find clusters comprised of clonally related Ig-VH may in fact harbor persistent B-cells in the CSF, or in other tissues. While it is possible that deeper sequencing of existing samples could have increased our sensitivity to identify persistent CSF Ig-VH clusters, and while there were some samples that did not generate productive sequences, we found no correlation between the average reads per cell and our ability to detect these clusters. Second, technical advances such as incorporation of unique molecular identifiers (UMIs) that aid in error correction and quantification were not a standard part of the sequencing method at the start of the study, and the initial method was maintained for consistency across this cohort. Ig-VH sequences obtained in this study overall 
Methods
Experimental Design
We hypothesized prior to initiating this study that in MS patients there would be a population of B-cell clones that persist in the CSF over time. Inclusion criteria for this observational study were 1) enrollment in the University of California at San Francisco (UCSF) Expression, Proteomics, Imaging, Clinical (EPIC)
Study (31) 
Sample Collection and Processing
7-30 mL of fresh CSF was centrifuged at 400g x 15 minutes at 4°C to separate a cell pellet from supernatant. PBMCs were isolated from whole blood via Ficoll gradient followed by red blood cell lysis and washing with phosphate buffered saline with 1% bovine serum albumin. Seven of 20 CSF samples and one of 20 PBMC samples were stored at -80°C as unsorted cell pellets (Table S3 ). The remaining CSF and PBMC samples were immediately blocked with FcR Block (Miltenyi Biotec, Bergisch Gladbach, Germany) and stained with fluorescent antibodies to cell surface markers -CD19, CD27, CD38, CD138, IgD; some samples were also stained for additional immune cell markers for experiments outside the scope of this study (antibody panels listed in Table S5, Table S6 ).
CSF and PB B-cell subsets were sorted as previously described (8) . Patient 4 had combined CD 27+/hi CSF sorted B-cells. CSF samples with concern for low Bcell count were bulk sorted -attaining flow cytometry data, but placing all CSF lymphocytes into a single sample tube rather than segregating into the above five subsets. B-cells were sorted directly into lysis buffer suitable for later RNA extraction (Qiagen, buffer RLT+ 1% β-mercaptoethanol) and stored at -80°C.
Immune Repertoire Sequencing
RNA was extracted using the RNeasy Mini kit for >200,000 cells or the Micro kit for <200,000 cells (Qiagen, Hilden, Germany). RNA was reverse transcribed using iScript reverse transcriptase (BioRad, Hercules, CA). IgG-VH and IgM-VH sequences spanning the variable region from framework 1 (IGHV FR1) to the constant region 1 were amplified using the Advantage2 PCR kit (Clontech, Mountain View, CA) and custom primers as described (8) 
Bioinformatics
Raw sequence FASTQ files were generated with Torrent Suite software (Thermo Fisher, Waltham, MA). A custom bioinformatics pipeline incorporating MiXCR (v2.1.3) (50) was used to identify IGHV and IGHJ germline segments and H-CDR3 for each sequence read. MiXCR first assembles reads with bases of quality scores >20 and then attempts to align reads with bases of lower (<20) quality to the already assembled reads. We applied a bioinformatics clustering approach as described previously (8) 
MRI Acquisition and Analysis
MRI scans at T1 and T2 were acquired on the same 3T Siemens scanner following a standardized protocol that included: 3D T1-weighted magnetization-prepared gradient echo images (MPRAGE), 3D fluidattenuated inversion recovery (FLAIR) and T2/PD images of the brain; whole spine T2-weighted and short tau inversion recovery (STIR) images. In addition, brain MPRAGE and whole spine T1-weighted images were acquired after administration of gadobutrol. Readings were performed by a neurologist with subspecialty interest in neuroimaging (AB, 11 years of experience) blinded to the clinical and immunological data.
Statistics
Graphpad Prism software (version 8) was used to perform statistical analyses: two-tailed unpaired t-tests were used to compare pairwise groups and Fisher's exact test was used to compare categorical variables.
ANOVA was used for comparisons between groups with approximate Gaussian distributions, with correction for multiple comparisons performed using the Sidak method. Kruskal-Wallis test with Dunn correction for multiple comparisons was used for multiple comparisons with non-parametric distributions.
Spearman correlation coefficient was used to determine correlation. p<0.05 was considered statistically significant.
Study approval
All studies were approved by the UCSF Institutional Review Board, and written informed consent was obtained from each participant prior to inclusion in the study. Table S1 . Patient characteristics based on presence or absence of CSF persistent Ig-VH Table S2 . Clinical CSF biometrics Table S3 . B-cell samples analyzed by IgSeq Table S4 : CSF Ig-VH cluster persistence rate is similar to PB Ig-VH cluster persistence rate. 10 MS patients, whose age at enrollment ranged from 24-52 were included. All were untreated at T1 with positive OCBs (one patient at T2 had 3 OCBs restricted to the CSF, the remaining had 5 or more; see Table   S2 
